Kronox Lab Sciences Limited (NSE:KRONOX)
India · Delayed Price · Currency is INR 133.74
+0.59 (0.44%)
Jun 3, 2026, 3:29 PM IST
Kronox Lab Sciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 1,012 | 1,002 | 898.62 | 955.78 | 822.47 |
Other Revenue | - | - | - | - | 1.33 |
| 1,012 | 1,002 | 898.62 | 955.78 | 823.8 | |
Revenue Growth (YoY) | 1.02% | 11.50% | -5.98% | 16.02% | 31.56% |
Cost of Revenue | 465.76 | 513.18 | 462.54 | 552.62 | 477 |
Gross Profit | 546.44 | 488.76 | 436.09 | 403.16 | 346.8 |
Selling, General & Admin | 74.03 | 47.54 | 62.29 | 70.27 | 57.82 |
Other Operating Expenses | 129.7 | 105.46 | 87.16 | 113.05 | 87.73 |
Operating Expenses | 224.21 | 166.82 | 162.33 | 198.28 | 165.84 |
Operating Income | 322.23 | 321.95 | 273.75 | 204.88 | 180.96 |
Interest Expense | -1.14 | - | - | -0.93 | -4.05 |
Interest & Investment Income | - | 17.76 | 10.17 | 4.25 | 3.2 |
Currency Exchange Gain (Loss) | - | 3 | 2.16 | 9.48 | 3.17 |
Other Non Operating Income (Expenses) | 51.94 | - | - | -0 | 0.01 |
EBT Excluding Unusual Items | 373.03 | 342.71 | 286.08 | 217.68 | 183.29 |
Gain (Loss) on Sale of Assets | - | - | - | 0.11 | 0.26 |
Other Unusual Items | - | - | - | 2.62 | - |
Pretax Income | 373.03 | 342.71 | 286.08 | 220.41 | 183.55 |
Income Tax Expense | 96.43 | 88.04 | 72.57 | 56.38 | 47.28 |
Net Income | 276.6 | 254.67 | 213.51 | 164.03 | 136.27 |
Net Income to Common | 276.6 | 254.67 | 213.51 | 164.03 | 136.27 |
Net Income Growth | 8.61% | 19.28% | 30.16% | 20.37% | 40.05% |
Shares Outstanding (Basic) | 37 | 37 | 37 | 39 | 39 |
Shares Outstanding (Diluted) | 37 | 37 | 37 | 39 | 39 |
Shares Change (YoY) | -0.74% | - | -4.09% | -0.91% | -3.59% |
EPS (Basic) | 7.51 | 6.86 | 5.75 | 4.24 | 3.49 |
EPS (Diluted) | 7.51 | 6.86 | 5.75 | 4.24 | 3.49 |
EPS Growth | 9.42% | 19.28% | 35.72% | 21.49% | 45.42% |
Free Cash Flow | 205.86 | 275.92 | 51.45 | 112.5 | 52.24 |
Free Cash Flow Per Share | 5.59 | 7.44 | 1.39 | 2.91 | 1.34 |
Dividend Per Share | 0.500 | 0.500 | 0.500 | - | - |
Gross Margin | 53.99% | 48.78% | 48.53% | 42.18% | 42.10% |
Operating Margin | 31.84% | 32.13% | 30.46% | 21.44% | 21.97% |
Profit Margin | 27.33% | 25.42% | 23.76% | 17.16% | 16.54% |
Free Cash Flow Margin | 20.34% | 27.54% | 5.73% | 11.77% | 6.34% |
EBITDA | 342.71 | 334.65 | 286.27 | 218.21 | 191.41 |
EBITDA Margin | 33.86% | 33.40% | 31.86% | 22.83% | 23.23% |
D&A For EBITDA | 20.48 | 12.7 | 12.51 | 13.33 | 10.45 |
EBIT | 322.23 | 321.95 | 273.75 | 204.88 | 180.96 |
EBIT Margin | 31.84% | 32.13% | 30.46% | 21.44% | 21.97% |
Effective Tax Rate | 25.85% | 25.69% | 25.37% | 25.58% | 25.76% |
Revenue as Reported | 1,064 | 1,027 | 914.4 | 974.98 | 833.4 |